These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37351874)

  • 1. Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs.
    Chang J; Karaca-Mandic P; Nikpay S; Jeffery MM
    JAMA Health Forum; 2023 Jun; 4(6):e231485. PubMed ID: 37351874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
    Li Y; Xu S
    JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B.
    Han D
    J Health Econ; 2023 May; 89():102754. PubMed ID: 37030057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.
    Jung J; Xu WY; Kalidindi Y
    Health Serv Res; 2018 Oct; 53(5):3528-3548. PubMed ID: 29355925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between initiation of 340B participation and hospital safety-net engagement.
    Nikpay SS; Buntin MB; Conti RM
    Health Serv Res; 2020 Apr; 55(2):157-169. PubMed ID: 32187392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US Hospital Service Availability and New 340B Program Participation.
    Owsley KM; Hasnain-Wynia R; Rooks RN; Tung GJ; Mays GP; Lindrooth RC
    JAMA Health Forum; 2024 May; 5(5):e240833. PubMed ID: 38700853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
    Feng K; Russo M; Maini L; Kesselheim AS; Rome BN
    JAMA Health Forum; 2024 Mar; 5(3):e235429. PubMed ID: 38551589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of the 340B Drug Pricing Program.
    Desai S; McWilliams JM
    N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
    Bond AM; Dean EB; Desai SM
    Health Aff (Millwood); 2023 May; 42(5):632-641. PubMed ID: 37126754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of medication access services at 340B and non-340B hospitals.
    Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
    Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 340B Participation and Safety Net Engagement Among Federally Qualified Health Centers.
    Watts E; McGlave C; Quinones N; Bruno JP; Nikpay S
    JAMA Health Forum; 2024 Oct; 5(10):e243360. PubMed ID: 39365605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
    DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
    JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between a Bundled Payment Program for Lower Extremity Joint Replacement and Patient Outcomes Among Medicare Advantage Beneficiaries.
    Sutherland A; Boudreau E; Bowe A; Huang Q; Liao JM; Flagg M; Cousins D; Antol DD; Shrank WH; Powers BW; Navathe AS
    JAMA Health Forum; 2023 Jun; 4(6):e231495. PubMed ID: 37355996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes.
    Keating NL; Jhatakia S; Brooks GA; Tripp AS; Cintina I; Landrum MB; Zheng Q; Christian TJ; Glass R; Hsu VD; Kummet CM; Woodman S; Simon C; Hassol A;
    JAMA; 2021 Nov; 326(18):1829-1839. PubMed ID: 34751709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community social vulnerability and the 340B Drug Pricing Program: Evaluating predictors of 340B participation among critical access hospital.
    Owsley KM; Karim SA
    J Rural Health; 2024 Sep; 40(4):720-727. PubMed ID: 38520681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of US Hospital Episode Spending for Acute Inpatient Conditions After the Patient Protection and Affordable Care Act.
    Ibrahim AM; Nuliyalu U; Lawton EJ; O'Neil S; Dimick JB; Gulseren B; Sinha SS; Hollingsworth JM; Engler TA; Ryan AM
    JAMA Netw Open; 2020 Nov; 3(11):e2023926. PubMed ID: 33226430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spending on and Use of Clinician-Administered Drugs in Medicare.
    Hyland MF; Sachs RM; Robillard L; Hayford TB; Bai G
    JAMA Health Forum; 2023 Sep; 4(9):e232941. PubMed ID: 37682554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.